Biomarker analysis was performed of patients in Keynote-199, evaluating tumor mutational burden (TMB), PD-L1 positive (combined positive score [CPS] ≥ 1) or negative (CPS < 1) disease, microsatellite instability (MSI), and tumor microenvironment-based 18-gene RNA expression profile; this abstract was presented at ASCO 2020 [53]. This evidence concerns the gene CD274 and neoplasm.